Stem Cells http://www.peprotech.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goodsell, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goodsell, D. S.

Stem Cells 2003;21:118-119 www.StemCells.com
© 2003 AlphaMed Press


FUNDAMENTALS OF CANCER MEDICINE

The Molecular Perspective: VEGF and Angiogenesis

David S. Goodsell

David S. Goodsell, Ph.D., Associate Professor, The Scripps Research Institute, Department of Molecular Biology, 10550 North Torrey Pines Road, La Jolla, California 92037, USA. Telephone: 858-784-2839; Fax: 858-784-2860; e-mail: goodsell{at}scripps.edu Website: http://www.scripps.edu/pub/goodsell

Our cells need a constant supply of oxygen to power their diverse molecular processes. This oxygen is delivered by the blood, so nearly all of our cells are within a tenth of a millimeter from a blood capillary. Tumor cells are no exception. If a collection of cancerous cells grows much larger than a millimeter, it will starve itself of oxygen and energy unless new blood vessels are built to provide a supply. For this reason, many cancer cells co-opt the normal processes of angiogenesis, the development of blood vessels, in order to build their own blood supply.

Vascular endothelial growth factor, or VEGF (shown in Fig. 1Go), is the key signal used by oxygen-hungry cells to promote growth of blood vessels. It binds to specialized receptors on the surfaces of endothelial cells (shown in Fig. 2Go) and directs them to build new vessels. After receiving this message, the cells build specialized proteases to break through the basal lamina, and migrate into the oxygen-starved region. Once there, the cells multiply and form into tubes, creating a new path for blood to flow.



View larger version (55K):
[in this window]
[in a new window]
 
Figure 1. VEGF and antibodies. Antibodies against VEGF have been shown to block binding to the VEGF receptors, and thus may be used to inhibit the growth of new blood vessels. In this illustration, VEGF is at the center, in red and purple, with two antibodies bound at top and bottom, in yellow and orange. VEGF is composed of two identical subunits. The core at the center forms the dimer and is involved in binding to the receptor. The small domains extending from the core of VEGF, which are built with different sizes in several subforms of VEGF, bind to heparin and to carbohydrates on the cell surface, modulating the activity of VEGF. Coordinates were taken from entries 1bj1, 2vgh, and 1hzh at the Protein Data Bank (http://www.pdb.org).

 


View larger version (109K):
[in this window]
[in a new window]
 
Figure 2. VEGF in action. VEGF, shown in red, binds to receptors, shown in yellow, on the surface of endothelial cells. The portion of receptor inside the cell is a tyrosine kinase enzyme, and the portion outside the cell binds to VEGF. VEGF brings together two receptors, so that inside the cell, the two kinase regions are close enough to add phosphate groups to each other. These phosphate groups are then recognized by the signaling apparatus inside the cell, beginning the process of angiogenesis.

 
Tumor cells use these same processes to create their own oxygen supply. Through mutation, they gain the ability to create abnormally large amounts of VEGF or to block the action of inhibitors of angiogenesis. This is often termed the "angiogenic switch," marking a key transition as cancer cells gain the ability to direct their own blood supply. Given a ready blood supply, the tumor can grow much larger. The switch also enhances the ability of the tumor to metastasize, since a custom-made blood supply can be constructed wherever new tumors begin to grow.

As you can imagine, this is an attractive process for the design of cancer therapy. By selectively inhibiting the growth of new blood vessels, we can starve tumor cells. Effective methods have been developed to do just this, using drugs or antibodies to block the formation of VEGF or the binding of VEGF to its receptors. Researchers have found, however, that these methods are effective for stopping the growth of a tumor, but generally not for reducing the size of an existing tumor. They are powerful tools, however, when used in combination with agents that attack other key points in the tumor cell.

FURTHER READING

    Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1996;1:27–31.

    Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 2000;19:6122–6129.[CrossRef][Medline]

    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.[CrossRef][Medline]




This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. Ray, C. M. Herring, T. A. Markel, P. R. Crisostomo, M. Wang, B. Weil, T. Lahm, and D. R. Meldrum
Deleterious effects of endogenous and exogenous testosterone on mesenchymal stem cell VEGF production
Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2008; 294(5): R1498 - R1503.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
T. A. Markel, M. Wang, P. R. Crisostomo, M. C. Manukyan, J. A. Poynter, and D. R. Meldrum
Neonatal stem cells exhibit specific characteristics in function, proliferation, and cellular signaling that distinguish them from their adult counterparts
Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2008; 294(5): R1491 - R1497.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
D. Sun, W.-J. Liu, K. Guo, J. J. Rusche, S. Ebbinghaus, V. Gokhale, and L. H. Hurley
The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex-interactive agents
Mol. Cancer Ther., April 1, 2008; 7(4): 880 - 889.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
D. Sun, K. Guo, J. J. Rusche, and L. H. Hurley
Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents
Nucleic Acids Res., October 20, 2005; 33(18): 6070 - 6080.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goodsell, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goodsell, D. S.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
http://www.peprotech.com/